sabrina essen sorted by
relevance

Admin29.08.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

5 Department of Medical Oncology, West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Admin28.07.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Thresholds were set at 400 counts for AURKA and 540 counts for RPA1 Overall and progression-free survival dependent on gene expression of AURKA, RAD50 and DDB2.
4005
Admin30.07.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

.
1307
Admin30.07.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
601
Admin01.08.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Keywords: BRCAness - BAP1; Malignant pleural mesothelioma - overall survival; Olaparib; PARP1.
8301
Admin10.08.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Consent for publication Not applicable.
5806
Admin20.07.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Low expression of AURKA and high expression of RAD50 and DDB2 resulted in prolonged overall survival A-C.
8707
Admin26.07.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

The authors declare no conflict of interest.
4301
Admin19.06.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

The present data can lead to a better understanding of the underlaying cellular mechanisms and leave the door wide open for new therapeutic approaches for this severe disease with infaust prognosis.
2301
Admin01.07.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

The median was used to set a cut-off between high and low gene expression Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, Jones D, George TJ Jr, Hromas R.
7102
Admin23.08.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Methods: We investigated the response of three MPM cell lines and lung fibroblasts serving as a control to treatment with pemetrexed, cisplatin and olaparib.
1204
Admin23.07.2021

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Ethics approval and consent to participate The study conforms to the principles outlined in the declaration of Helsinki and was approved by the institutional review board Ethics Committee of the Medical Faculty of the University Duisburg-Essen , protocol no.
108